Significant improvement in oxygenation

INOMAX is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.

Read Important Safety Information.

Dosage and administration

  • Recommended dosing of 20 ppm
  • INOMAX must be administered using the INOmax DSIR, INOmax DS, or INOvent nitric oxide delivery systems
  • Users of INOMAX or nitric oxide delivery systems must complete a comprehensive training program
  • Maintain treatment for up to 14 days, or until underlying oxygen desaturation has resolved
  • To wean INOMAX, downtitrate in several steps, pausing several hours at each step to monitor for hypoxemia
  • Abrupt discontinuation of INOMAX may lead to increasing pulmonary artery pressure and worsening oxygenation even in neonates with no apparent response to nitric oxide for inhalation
  • Users have 24/7 customer and technical support provided by Mallinckrodt Pharmaceuticals at 877-566-9466
  • Keep available an independent backup INOMAX delivery system

Please see Full Prescribing Information.